BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...steatohepatitis company’s C-suite since December, when founder Mark Pruzanski left as president and CEO. CMO Jason Campagna joined Q32 Bio Inc....
BioCentury | Mar 10, 2021
Management Tracks

Ex-BARDA Director Bright joins Rockefeller Foundation; plus Lilly, Q32 Bio, Apollomics, Axial and Grip

...in June by VP and Deputy General Counsel Alonzo Weems. Jason Campagna joined inflammatory and autoimmune play Q32 Bio Inc....
...as chairman. Ludwig was CEO and chairman at Becton Dickinson and Co. (NYSE:BDX). BC Staff Eli Lilly and Co. Q32 Bio Inc. Apollomics...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...was most recently SVP of global medical affairs and interim CMO at Portola Pharmaceuticals Inc. (NASDAQ:PTLA). Q32 Bio Inc....
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...By BioCentury Staff Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised...
...Frumtak Ventures.TARGETSIL-7R - Interleukin-7 receptorROR1 – Receptor tyrosine kinase-like orphan receptor 1 BC Staff CStone Pharmaceuticals Co. Ltd. Q32 Bio Inc. Centrexion...
BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...a director at Day One Biopharmaceuticals LLC, a pediatric cancer company launched last month; and Q32 Bio Inc....
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

...a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio Inc....
...aberrant T and B cell activity, like Sjögren syndrome, pneumatic mastocytosis and lupus. COMPANY PROFILE Q32 Bio Inc....
...receptor Elizabeth S. Eaton, Staff Writer Bristol Myers Squibb Co. Complement 5 (C5) Complement 3 (C3) Interleukin-7 (IL-7) receptor (CD127) complement pathway complement Q32 Bio Inc....
Items per page:
1 - 6 of 6
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...steatohepatitis company’s C-suite since December, when founder Mark Pruzanski left as president and CEO. CMO Jason Campagna joined Q32 Bio Inc....
BioCentury | Mar 10, 2021
Management Tracks

Ex-BARDA Director Bright joins Rockefeller Foundation; plus Lilly, Q32 Bio, Apollomics, Axial and Grip

...in June by VP and Deputy General Counsel Alonzo Weems. Jason Campagna joined inflammatory and autoimmune play Q32 Bio Inc....
...as chairman. Ludwig was CEO and chairman at Becton Dickinson and Co. (NYSE:BDX). BC Staff Eli Lilly and Co. Q32 Bio Inc. Apollomics...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...was most recently SVP of global medical affairs and interim CMO at Portola Pharmaceuticals Inc. (NASDAQ:PTLA). Q32 Bio Inc....
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...By BioCentury Staff Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised...
...Frumtak Ventures.TARGETSIL-7R - Interleukin-7 receptorROR1 – Receptor tyrosine kinase-like orphan receptor 1 BC Staff CStone Pharmaceuticals Co. Ltd. Q32 Bio Inc. Centrexion...
BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...a director at Day One Biopharmaceuticals LLC, a pediatric cancer company launched last month; and Q32 Bio Inc....
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

...a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio Inc....
...aberrant T and B cell activity, like Sjögren syndrome, pneumatic mastocytosis and lupus. COMPANY PROFILE Q32 Bio Inc....
...receptor Elizabeth S. Eaton, Staff Writer Bristol Myers Squibb Co. Complement 5 (C5) Complement 3 (C3) Interleukin-7 (IL-7) receptor (CD127) complement pathway complement Q32 Bio Inc....
Items per page:
1 - 6 of 6